P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Lee, Seung-Yul, Jeong, Young-Hoon, Ho Yun, Kyeong, Young Cho, Jae, Gorog, Diana, Angiolillo, Dominick J., Jin Won, Kim and Jang, Yangsoo (2023) P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study. JACC: Cardiovascular Interventions, 16 (15). pp. 1845-1855. ISSN 1876-7605

Copy

This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

Item Type	Article
Additional information	© 2023 by the American College of Cardiology Foundation. Published by Elsevier. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.jcin.2023.05.035
Date Deposited	15 May 2025 15:12
Last Modified	04 Jun 2025 17:18